세계의 인플루엔자 백신 시장 : 동향, 예측, 경쟁 분석(-2030년)

Influenza Vaccine Trends and Forecast

The future of the global influenza vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global influenza vaccine market is expected to reach an estimated $11.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising demand for more effective and less invasive influenza vaccines, growing awareness of the benefits of influenza vaccines, and supportive government initiatives to promote influenza vaccination.

• Lucintel forecasts that inactivated is expected to witness higher growth over the forecast period due to growing demand for these vaccinations given to its safety and effectiveness.
• Within this market, hospital & retail pharmacy is expected to witness highest growth over the forecast period as they are the easiest and most accessible locations to acquire a flu vaccine.
• North America is expected to witness highest growth over the forecast period due to high prevalence of influenza, availability of well-established healthcare system, and high preference for vaccination in the region.

Emerging Trends in the Influenza Vaccine Market

Emerging trends in the influenza vaccine market reflect innovations in vaccine technology, expanded access, and evolving public health strategies. These trends are shaping the future of influenza prevention and treatment globally.

• Development of Quadrivalent and High-Dose Vaccines: The trend towards quadrivalent and high-dose vaccines is prominent. Quadrivalent vaccines cover four strains of the influenza virus, offering broader protection. High-dose vaccines are designed for older adults to improve immune response. These developments aim to enhance efficacy and provide better protection against influenza.
• Focus on Vaccine Innovation and Personalized Vaccines: Innovation in vaccine technology, including personalized vaccines tailored to individual genetic profiles, is gaining momentum. These advances promise more effective and targeted influenza prevention, potentially increasing vaccine uptake and improving overall public health outcomes.
• Increased Emphasis on Annual Vaccination: There is a growing emphasis on annual influenza vaccination to address seasonal variations in flu strains. Annual vaccination campaigns are becoming more widespread, aiming to boost vaccine coverage and reduce the incidence of influenza outbreaks each year.
• Expansion of Vaccination Programs to Underserved Areas: Expanding vaccination programs to underserved and rural areas is a key trend. Initiatives to increase vaccine accessibility in low-income and remote regions are being implemented to ensure broader coverage and reduce the disparity in influenza prevention.
• Integration with Digital Health Solutions: Integration of digital health solutions, such as electronic health records and mobile health apps, is improving vaccine tracking and management. Digital tools help streamline vaccination processes, enhance public health communication, and increase vaccine adherence rates.

Emerging trends such as the development of quadrivalent and high-dose vaccines, focus on vaccine innovation, increased emphasis on annual vaccination, expansion to underserved areas, and integration with digital health solutions are reshaping the influenza vaccine market. These trends enhance vaccine effectiveness, accessibility, and overall public health strategies.

Recent Developments in the Influenza Vaccine Market

Recent developments in the influenza vaccine market are marked by technological advancements, regulatory updates, and improved public health strategies. These developments are driving changes in vaccine effectiveness and accessibility.

• Introduction of Quadrivalent Vaccines: The introduction of quadrivalent vaccines, which cover an additional strain compared to trivalent vaccines, represents a significant development. These vaccines offer broader protection and are becoming the standard for influenza prevention, improving overall efficacy and reducing seasonal flu incidence.
• Advancements in High-Dose and Adjuvanted Vaccines: High-dose and adjuvanted vaccines have been developed to enhance immune response, especially in older adults. These vaccines are designed to address age-related declines in immunity, providing better protection and reducing the risk of severe influenza-related complications.
• Expansion of Vaccine Access Programs: Efforts to expand vaccine access through government subsidies and public health programs have increased. These programs aim to make vaccines more affordable and accessible, particularly in underserved populations and rural areas, thereby improving vaccination rates and public health outcomes.
• Emergence of New Vaccine Formulations: New vaccine formulations, including those with improved protection against multiple strains, have been introduced. These formulations enhance the ability to address evolving influenza viruses and improve vaccine effectiveness, contributing to better seasonal flu management.
• Global Collaboration for Vaccine Distribution: Global collaboration among governments, pharmaceutical companies, and health organizations has improved vaccine distribution. These partnerships help ensure that vaccines reach diverse populations, including those in low- and middle-income countries, enhancing global influenza prevention efforts.

Recent developments such as the introduction of quadrivalent vaccines, advancements in high-dose and adjuvanted vaccines, expansion of access programs, emergence of new formulations, and global collaboration are significantly impacting the influenza vaccine market. These advancements enhance vaccine effectiveness, accessibility, and overall public health outcomes.

Strategic Growth Opportunities for Influenza Vaccine Market

Strategic growth opportunities in the influenza vaccine market are driven by advancements in vaccine technology, increased global vaccination efforts, and evolving public health needs. These opportunities present potential for market expansion and improved health outcomes.

• Expansion into Emerging Markets: Expanding influenza vaccination programs into emerging markets offers significant growth opportunities. Targeting regions with low vaccination coverage and high disease burden can drive market growth and improve global health by reducing the incidence of influenza.
• Development of Next-Generation Vaccines: Investing in the development of next-generation influenza vaccines, such as those with broader strain coverage and improved efficacy, presents growth potential. These vaccines can address current limitations and meet evolving public health needs, driving market innovation and expansion.
• Integration with Public Health Programs: Integrating influenza vaccines with existing public health programs, such as routine immunizations and seasonal health campaigns, offers growth opportunities. By incorporating vaccines into comprehensive health strategies, vaccination rates can be increased, leading to better disease prevention and management.
• Advancements in Digital Health and Vaccine Tracking: Leveraging digital health solutions for vaccine tracking and management provides growth opportunities. Digital tools, including mobile apps and electronic health records, can enhance vaccination processes, improve adherence rates, and streamline public health efforts.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with governments, NGOs, and private sector players can enhance vaccine distribution and access. These partnerships can facilitate market growth by improving vaccine availability, reducing costs, and expanding coverage to underserved populations.

Strategic growth opportunities in the influenza vaccine market include expansion into emerging markets, development of next-generation vaccines, integration with public health programs, advancements in digital health, and strategic partnerships. These opportunities drive market expansion, improve vaccine accessibility, and enhance overall public health outcomes.

Influenza Vaccine Market Driver and Challenges

The influenza vaccine market is influenced by a range of drivers and challenges, including technological advancements, economic factors, and regulatory issues. Understanding these factors is crucial for navigating the market and fostering growth.

The factors responsible for driving the influenza vaccine market include:

1. Technological Advancements in Vaccine Development: Technological advancements in vaccine development, such as new formulations and improved delivery methods, drive market growth. These innovations enhance vaccine efficacy and address emerging influenza strains, improving overall public health outcomes.

2. Increased Public Awareness and Health Campaigns: Increased public awareness and health campaigns about the importance of influenza vaccination boost vaccine uptake. Educational initiatives and targeted campaigns contribute to higher vaccination rates and better prevention of seasonal flu.

3. Government Funding and Subsidies: Government funding and subsidies support influenza vaccination programs and make vaccines more accessible. Financial support helps reduce vaccine costs and promotes broader coverage, particularly in underserved and high-risk populations.

4. Rising Incidence of Influenza and Related Complications: The rising incidence of influenza and related complications drives demand for effective vaccines. Increased flu outbreaks and severe cases highlight the need for improved vaccination strategies and contribute to market growth.

5. Global Health Partnerships and Collaborations: Global health partnerships and collaborations enhance vaccine distribution and access. Collaborative efforts between governments, NGOs, and private organizations improve vaccine availability and facilitate global influenza prevention initiatives.

Challenges in the influenza vaccine market are:

1. Vaccine Hesitancy and Misinformation: Vaccine hesitancy and misinformation pose challenges to increasing vaccination rates. Addressing public concerns and providing accurate information are essential for improving vaccine uptake and ensuring the success of vaccination programs.

2. High Vaccine Costs: High vaccine costs can limit access, particularly in low-income regions. Addressing affordability issues is crucial for improving vaccine accessibility and achieving broader coverage.

3. Regulatory and Compliance Challenges: Navigating complex regulatory and compliance requirements can be challenging. Ensuring adherence to varying regulations across regions adds complexity to vaccine development and market entry.

Major drivers of the influenza vaccine market include technological advancements, increased public awareness, government funding, rising influenza incidence, and global health partnerships. Key challenges include vaccine hesitancy, high costs, and regulatory complexities. Addressing these drivers and challenges is essential for market growth and improving public health outcomes.

List of Influenza Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies influenza vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the influenza vaccine companies profiled in this report include-

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Influenza Vaccine by Segment

The study includes a forecast for the global influenza vaccine by vaccine type, distribution channel, and region.

Influenza Vaccine Market by Vaccine Type [Analysis by Value from 2018 to 2030]:

• Inactivated
• Live Attenuated

Influenza Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

Influenza Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Influenza Vaccine Market

Recent developments in the influenza vaccine market highlight advancements in vaccine technology, regulatory changes, and global vaccination strategies. These developments are shaping the market landscape in key regions including the United States, China, Germany, India, and Japan.

• United States: In the U.S. the influenza vaccine market has seen advancements with the introduction of quadrivalent vaccines, covering additional strains for broader protection. Enhanced formulations with higher efficacy rates are being adopted, and there is increased emphasis on annual vaccination campaigns. The FDA has also approved new vaccines with improved immune responses, targeting diverse age groups and high-risk populations.
• China: China has focused on expanding its influenza vaccination programs with new domestic vaccine formulations. The government has increased funding and subsidies to promote higher vaccine uptake. Recent developments include the approval of new influenza vaccines and efforts to improve vaccination coverage in rural and underserved areas, aiming to mitigate seasonal flu outbreaks effectively.
• Germany: Germany has made strides in the influenza vaccine market by incorporating newer, more effective vaccines into its national immunization program. The introduction of high-dose and adjuvanted vaccines for older adults reflects an effort to boost vaccine efficacy. Additionally, public health campaigns have been intensified to encourage higher vaccination rates across different demographics.
• India: In India, the focus has been on increasing vaccine accessibility and affordability. New initiatives include the launch of cost-effective influenza vaccines and expansion of vaccination programs in rural areas. Government partnerships with pharmaceutical companies aim to enhance distribution and coverage, addressing the high burden of seasonal influenza in the country.
• Japan: Japan has advanced its influenza vaccine market by updating vaccination guidelines and improving vaccine formulations. The introduction of vaccines with enhanced protection against multiple strains and extended vaccination campaigns for both adults and children are notable. Japan is also investing in research to develop more effective vaccines and improve public health responses to influenza.

Features of the Global Influenza Vaccine Market

Market Size Estimates: Influenza vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Influenza vaccine market size by vaccine type, distribution channel, and region in terms of value ($B).

Regional Analysis: Influenza vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, distribution channels, and regions for the influenza vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the influenza vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the influenza vaccine market size?

Answer: The global influenza vaccine market is expected to reach an estimated $11.2 billion by 2030.

Q.2 What is the growth forecast for influenza vaccine market?

Answer: The global influenza vaccine market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the influenza vaccine market?

Answer: The major drivers for this market are rising demand for more effective and less invasive influenza vaccines, growing awareness of the benefits of influenza vaccines, and supportive government initiatives to promote influenza vaccination.

Q4. What are the major segments for influenza vaccine market?

Answer: The future of the influenza vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key influenza vaccine market companies?

Answer: Some of the key influenza vaccine companies are as follows:

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Q6. Which influenza vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that inactivated is expected to witness higher growth over the forecast period due to growing demand for these vaccinations given to its safety and effectiveness.

Q7. In influenza vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to high prevalence of influenza, availability of well-established healthcare system, and high preference for vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the influenza vaccine market by vaccine type (inactivated and live attenuated), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Influenza Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Influenza Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Influenza Vaccine Market by Vaccine Type
  • 3.3.1: Inactivated
  • 3.3.2: Live Attenuated
• 3.4: Global Influenza Vaccine Market by Distribution Channel
  • 3.4.1: Hospital & Retail Pharmacies
  • 3.4.2: Government Suppliers
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Influenza Vaccine Market by Region
• 4.2: North American Influenza Vaccine Market
  • 4.2.1: North American Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated 4.2.2: North American Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.3: European Influenza Vaccine Market
  • 4.3.1: European Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.3.2: European Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.4: APAC Influenza Vaccine Market
  • 4.4.1: APAC Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.4.2: APAC Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.5: ROW Influenza Vaccine Market
  • 4.5.1: ROW Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.5.2: ROW Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Influenza Vaccine Market by Vaccine Type
  • 6.1.2: Growth Opportunities for the Global Influenza Vaccine Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Influenza Vaccine Market by Region
• 6.2: Emerging Trends in the Global Influenza Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Influenza Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Influenza Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GSK
• 7.2: AstraZeneca
• 7.3: SINOVAC
• 7.4: Pfizer
• 7.5: Vaxess Technologies
• 7.6: CSL
• 7.7: EMERGENT